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Objectives: To study the role of the innate immune response in the higher mortality of hospital-
than of community-acquired infections, in febrile medical patients.
Methods: We studied presumably immunocompetent patients with new-onset fever and a
clinically presumed focus of infection (N = 212) at a university department of internal medicine.
Clinical and microbiological data were collected for 2 days from inclusion, and circulating
complement activation product C3a, secretory phospholipase A2, interleukin (IL)-6, procalcito-
nin, and elastase-a1-antitrypsin were measured. Patients were followed for septic shock and
outcome, up to a maximum of 7 and 28 days after inclusion, respectively. Infection was
considered hospital-acquired if it developed at least 72 h after admission.
Results: Fifty-four patients had hospital-acquired infections and 158 had community-acquired
infections, with septic shock and mortality rates of 15% and 24%, and 4% and 6% ( p = 0.001),
respectively. Bloodstream infection predisposed to septic shock and the latter predisposed to
death. Bloodstream infection was relatively more common in septic shock originating from
community-acquired infection and was associated with an innate immune response in both
hospital- and community-acquired infection, as judged from circulating immune variables. In
contrast, circulating C3a, IL-6, and procalcitonin were more elevated when septic shock devel-
oped following hospital- than community-acquired infection, independent of infectious focus.
The levels of C3a, secretory phospholipase A2, IL-6, and elastase-a1-antitrypsin were more
elevated in ultimate non-survivors than in survivors in both infection groups.
Conclusions: The data suggest that rates of septic shock and mortality from hospital- vs.
community-acquired infections in febrile medical patients are not increased by impaired innate
immunity. In contrast, proinflammatory factors may be particularly useful to predict a downhill
course in hospital-acquired infections.
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Abetter understanding of themechanisms leading tomortality
during hospital-acquired infections may have important pre-
ventive and therapeutic implications. Indeed, hospital-
acquired infections are increasingly common and may affect
medical patients almost as often as surgical ones, even though
the latter have been studied more often.1—6 According to the
literature, in studies mainly using non-infected controls for
comparison, risk factors include (intravascular) devices, inter-
ventions, and other external and patient-related factors.2,6—9
Hospital-acquired infections carry a highermortality rate than
community-acquired infections, and contributing factors
include underlying disease, bloodstream infection, and asso-
ciated septic shock.2,3,6,7,9—11
Even though hemato-oncologic disease and the use of
cytostatic drugs are well known to lead to immunocompro-
mise in the host, with an increased susceptibility to fatal
infections in the hospital, the role of innate immunity in
hospital- vs. community-acquired infections and the effect
on outcome are unclear in presumably immunocompetent
patients.2,8 The innate immune response to infection
involves various cellular and humoral effector mechanisms,
which are reflected by changes in circulating levels of a
variety of mediators, including complement activation pro-
ducts, cytokines, lipid mediators, procalcitonin, and neutro-
phil degranulation products.1,3,12—32 Indeed, plasma levels of
these factors may aid in predicting bloodstream infection,
septic shock, and mortality from microbial infections even
though their value varies among studies.1,3,4,7,12—27,29—32
Some of the studies have been performed on predominantly
hospital- or intensive care unit-acquired infections,1—3,13—
15,19,21,22,24,27 on community-acquired infections treated in
the hospital,16,18,23,25,26,29,31,32 or both,17 and this difference
might also explain some of the variation in results.14
We hypothesized that the development of septic shock
andmortality are associated with innate immune suppression
for a given clinical andmicrobiological focus, during hospital-
vs. community-acquired infections, even in the prior immu-
nocompetent host. Therefore, we prospectively studied the
demographic, clinical, microbiological, and innate immuno-
logical characteristics of febrile medical patients with hos-
pital- or community-acquired infections, in the absence of
hemato-oncologic disease and cytostatic treatment.
Patients and methods
Patients
Three hundred consecutive patients with new-onset fever
(body temperature >38 8C axillary or 38.3 8C rectally),
admitted to the department of internal medicine at a uni-
versity hospital over a 1-year period, have been described
elsewhere.20,24 Here we report on the 212 patients for whom
a clinical focus of infection was presumed. A previous paper
on this cohort dealt with clinical risk factors for hospital-
acquired infection and death.9 The study was approved by
the local ethics committee. All patients or their closest
relatives gave informed consent. Exclusion criteria were
pregnancy, shock, and a life expectancy of less than 24 h.
Moreover, patients who had received recent cytokine orcytostatic drug treatment for solid tumors and malignant
hematological diseases, and those potentially having an
overtly abnormal host response, for instance in the course
of AIDS (related to HIV), were excluded. Patients were cared
for by physicians not involved in the study. Diagnostic and
therapeutic decisions were made by these physicians inde-
pendently of the study protocol. The assessment of the
clinically presumed focus of infection by the treating physi-
cian was supplemented, if necessary, by imaging techniques.
At inclusion, demographic data and clinical characteris-
tics were recorded. These included age, gender, use of
immunocompromising drugs (such as corticosteroids given
in the absence of hemato-oncologic disease), prior cardio-
vascular, endocrine (and diabetes), genitourinary, neurolo-
gical, or respiratory disease, active malignancies, and
surgery within two months prior to inclusion. The Interna-
tional Classification of Disease (ICD-9) definitions were used
to describe the disease states. We recorded the use of
devices and interventions. Clinical variables (temperature,
respiratory rate, heart rate, mean arterial blood pressure
(MAP), score on the Glasgow Coma Scale (GCS), and leuko-
cyte count) were measured at inclusion and in the morning on
the first and second days thereafter (days 0, 1, and 2).
Infection was considered hospital-acquired if it developed
at least72 hafteradmission intothehospital.Allotherpatients
were considered to have community-acquired infection. An
estimate of the time interval between development of fever
and inclusion in the study was made. The clinically presumed
focusof infectionandall localandbloodcultureresultsduringa
follow-up period of 7 days after inclusion were noted. Patients
were followed for 7 days for the development of septic shock
andfor28days foroutcome.Septic shockwasdefinedasafall in
arterial blood pressure below 90 mmHg (or a systolic decrease
>40 mmHg in previous hypertension) in the presence of sys-
temic inflammatory response syndrome (SIRS) criteria, with
fever (or hypothermia), tachycardia, tachypnea, and leuko-
cytosis (or leukopenia).5 Patients discharged from the hospital
within the follow-up period were classified as survivors.
Microbiology
Local specimens formicrobiological evaluationwere collected
at admission. Two blood cultures were obtained by venipunc-
ture at inclusion and thereafter as judged necessary by the
treating physician. Blood cultures were processed for aerobic
and anaerobic cultures (Bactec 9120/9240, Becton Dickinson,
Erembodegem, Belgium). Bottles were incubated for a max-
imum of 7 days. If the analyzers showed growth, Gram stains
were prepared and identification and sensitivity cultures were
processed. Blood cultures containing Staphylococcus epider-
midis were considered contaminated if only one bottle reve-
aled growth and there were no indwelling vascular catheters.
Local specimenswereprocessedusing standardprocedures.An
infectionwasconsideredproven ifmicrobiological resultswere
positive and if the treating physician decided to prescribe or
continue antimicrobial therapy based on these results.
Immune markers
Blood samples for determination of plasma levels of inflam-
matory mediators were obtained at inclusion and daily
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soybean trypsin inhibitor (100 mg/ml, final concentration),
ethylene diamine tetraacetate (EDTA, 10 mmol/l), and
benzamidine (10 mmol/l) to prevent in vitro activation.
All tubes were centrifuged for 10 min at 1300 g, and ali-
quots of the plasma were stored immediately at 70 8C
until assays were performed. Factors of innate immunity
were measured in plasma, as described previously.20,24
Complement activation was measured by circulating levels
of C3a with a radioimmunoassay (RIA). In this test, binding
of 125I-labelled C3 to anti-C3a antibodies immobilized onto
a solid phase (Sepharose) was inhibited by C3a present in
plasma samples. To prevent interference by native C3,
plasma samples were first precipitated with 11% (wt/vol)
polyethylene glycol 6000, after which the supernatant was
tested. Normal values in healthy volunteers are 5 nmol/l.
Secretory phospholipase A2 (sPLA2) was determined by
enzyme-linked immunosorbent assay (ELISA). Normal sPLA2
levels in healthy volunteers are below 5 ng/ml. Plasma IL—
6 was measured with a modified ELISA. Results were
related to a dose—response curve obtained with recombi-
nant human IL—6 and expressed in pg/ml. Normal values in
healthy volunteers are less than 10 pg/ml. Procalcitonin
(PCT) was measured using an immunoluminometric assay
and elastase-a1-antitrypsin (EA) was determined by RIA.
Normal values for PCT are <0.5 ng/ml (lower limit of
detection 0.08 ng/ml) and for EA are <100 ng/ml.
Statistics
Day 0, peak, and nadir values were selected, where appro-
priate. Categorical variables were compared using the Chi-
square or Fisher’s exact test and continuous variables with
the Mann—Whitney U-test. Multiple logistic regression (for-
ward method on the basis of likelihood ratio) was done for
differences in categorical variables according to infection
groups on the one hand and septic shock and outcome groups
on the other, and their first-order interactions. Interactions
were included to determine whether responses depended on
the infection group. A similar procedure was done for con-
tinuous variables after logarithmic transformation to reach
normal distributions, using univariate analysis of variance,
with time to inclusion (and focus) as a covariate. Areas under
the receiver operating characteristic curves (AUC ROC) were
determined in order to find the best predictors. Backward
multiple logistic regression was done to evaluate the con-
tribution of clinical and immune variables in predicting septic
shock and mortality. Exact p values 0.05 and >0.001 are
given, and a p-value of 0.05 was considered statistically
significant. Data are expressed as median (range) or mean
 standard error of the mean (SEM) for graphics.
Results
Patient characteristics
Fifty-four patients had a hospital-acquired infection and 158
patients had a community-acquired infection (Table 1). Over-
all, the prevalence of septic shock was 7% and the 28-day
mortality rate was 11%. Hospital-acquired infection predis-
posed to bloodstream infection (p = 0.046), and both, in turn,predisposed to septic shock,whilebloodstream infectionwas a
greater risk factor for septic shock in community- than in
hospital-acquired infection (p = 0.003 for hospital-acquired
infection and p = 0.004 for interaction of community-acquired
infection with bloodstream infection). Indeed, 50% (4/8) of
hospital-acquired infections and 67% (4/6) of community-
acquired infections leading to septic shock were associated
withbloodstreaminfection.Femalegenderwasarisk factor for
bloodstream infection, particularly in hospital-acquired infec-
tions (p = 0.003 for interaction), while a respiratory focus
protected (p < 0.001). Female gender (p = 0.038), genitour-
inary disease (p = 0.034) and focus (p = 0.059) as well as
positive local cultures (p = 0.006) were risk factors for septic
shock, although there was an interaction between female
gender and hospital-acquired infection only (p = 0.007). Hos-
pital-acquired infection and septic shock predisposed to mor-
tality (p = 0.009 and p < 0.001, respectively). Indeed, septic
shock was associated with mortality in 75% (6/8) of hospital-
and 33% (2/6) of community-acquired infections. When death
wasconsideredonclinicalgroundstobecaused,atleast inpart,
by infection (n = 17), mortality was again higher in hospital-
acquired infections and septic shock (p = 0.008 and p < 0.001,
respectively). The time to inclusion was shorter for hospital-
than community-acquired infections, but there was no inter-
action with rates of bloodstream infection or septic shock.
Clinical variables in contrast groups (Table 2)
There were no interactions between hospital- or community-
acquired infection and bloodstream infection or septic shock,
except for a relatively low nadir GCS in septic shock from
community-acquired infections. Other variables were ele-
vated in bloodstream infection and septic shock, both in
hospital- and community-acquired infection, even in the
presence of baseline differences between the latter.
Innate immunity in contrast groups (Table 3,
Figures 1—3)
Bloodstreaminfectionduringhospital-acquired infectionsgen-
erated less peak C3a, day 0 sPLA2 and PCT levels than during
community-acquired infection (Table 3). However, peak sPLA2
(p = 0.032), day 0 and peak IL-6 (p = 0.002 or lower), PCT
(p = 0.005), and EA were higher when blood or local micro-
biologicalcultureswerepositive, regardlessof infectiongroup.
In contrast, the circulating innate immune response variables
were generally higher in septic shock from hospital- than from
community-acquired infections. However, the prognostic
value was independent of infection group. Nevertheless, the
IL-6 levelswerehigher innon-survivors consideredtohavedied
directly as a consequence of hospital-acquired infections
(n = 11) than in non-survivors of community-acquired infec-
tions (n = 6, p = 0.05 for interaction). There was no contribu-
tion of time to inclusion and distribution of infectious foci.
Prediction and multivariate analyses for peaks or
nadirs of continuous values
Only a high peak temperature predicted bloodstream infec-
tion in hospital-acquired infection (AUC ROC curve 0.67,
p = 0.052). Among the clinical and innate immune response
Table 1 Characteristics of infection groups
Hospital-acquired
infection (N = 54)
Community-acquired
infection (N = 158)
p
Age, years 66 (27—92) 64 (17—97)
Gender, M/F 26 (48)/28 (52) 81 (51)/77 (49)
From home 48 (89) 143 (91)
Corticosteroids 7 (13) 8 (5)
Other immunosuppressive drugs 7 (13) 24 (15)
Prior cardiovascular disease 17 (31) 34 (22)
Prior endocrine disease (and diabetes mellitus) 15 (28) 36 (23)
Active malignant disease 14 (26) 28 (18)
Prior genitourinary disease 11 (20) 15 (9) 0.052
Prior neurological disease 7 (13) 17 (11)
Prior respiratory disease 7 (13) 16 (10)
Recent surgery 9 (17) 19 (12)
Devices/interventions in hospital 28 (52) 22 (14) 0.001
Biliary drainage 3 (5) 3 (2)
Thoracic drainage 4 (7) 2 (1)
Urinary catheter 3 (5) 3 (2)
Intravascular catheter 7 (13) 5 (3)
Hemodialysis 2 (4) 1 (0.6)
Peritoneal dialysis 1 (2) 2 (1)
Presumed focus of infection <0.001
Intravascular 6 (11) 4 (2) <0.001
Respiratory 19 (35) 71 (45)
Skin/bone/joints 12 (22) 27 (17)
GU tract 4 (7) 29 (18)
GI tract 13 (24) 23 (15)
Miscellaneous 0 4 (2)
Proven infection 29 (54) 77 (49)
Positive local culture/bloodstream infection 23 (43)/17 (31) 61 (39)/29 (18) 0.056
Escherichia coli 2 (4) 8 (5)
Salmonella spp 0 2 (1)
Morganella morgagni 1 (2) 0
Klebsiella pneumoniae 1 (2) 1 (0.6)
Pseudomonas aeruginosa 0 2 (1)
Bacteroides spp 1 (2) 2 (1)
Staphylococcus aureus 2 (4) 8 (5)
Staphylococcus epidermidis 4 (7) 1 (0.6)
Streptococcus spp 3 (5) 5 (3)
Polymicrobial 3 (5) 0
Septic shock 8 (15) 6 (4) 0.009
Mortality 13 (24) 10 (6) 0.001
Time to inclusion, h 2 (0.5—74) 28 (0—383) <0.001
Median (range) or number of patients (percentage), where appropriate. GU, genitourinary; GI, gastrointestinal.
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were most helpful in predicting septic shock and peak
respiratory rate in predicting death from hospital-acquired
infections (AUC 0.82, p = 0.001). The latter was followed by
peak IL-6, also if infection-related mortality was considered.
In community-acquired infection, peak C3a and EA were the
best predictors among the innate immune response variables
for bloodstream infection (AUC 0.75 or higher, p < 0.001).
Peak EA was most helpful in predicting septic shock (AUC
0.77, p = 0.024) and mortality (AUC 0.79, p = 0.003),
whereas, among the clinical variables, a low nadir GCS scorewas most predictive for septic shock and mortality (AUC 0.75
or higher, p = 0.033).
In multiple logistic regression for hospital-acquired infec-
tions, only peak temperature ( p = 0.050) was predictive of
bloodstream infection, while other variables did not contri-
bute. Peak IL-6 and EA together predicted septic shock,
whereas bloodstream infection and other variables did not
contribute. In turn, peak IL-6 did not contribute to prediction
of (infection-related) mortality by peak respiratory rate and
septic shock. In community-acquired infections, the peak
EA was predictive ( p = 0.002), independently from other
Table 2 Clinical signs and symptoms according to infection groups, bloodstream infection, and septic shock
Hospital-acquired Community-acquired p
Bloodstream (n = 17) No bloodstream (n = 37) Bloodstream (n = 29) No bloodstream (n = 127)
Temperature, 8C
Day 0 39.1 (38.4—40.0) 38.7 (38.2—40.0) 39.3 (38.4—40.5) 39.0 (38.0—41.3) 0.021 HI
Peak 39.4 (38.4—40.4) 39.1 (38.3—40.2) 39.8 (38.4—40.8) 39.2 (38.3—41.3) 0.003 BI
Respiratory rate, b/min
Day 0 24 (12—50) 24 (10—48) 24 (17—36) 24 (13—48)
Peak 24 (12—54) 28 (15—48) 30 (18—44) 30 (14—56)
Heart rate, b/min
Day 0 112 (60—154) 104 (72—148) 100 (72—130) 100 (56—160) 0.018 HI
Peak 120 (84—170) 108 (80—148) 104 (84—130) 104 (76—160) 0.001 HI
Leukocytes, 109/l
Day 0 12.5 (2.6—38.4) 12.0 (4.8—41.4) 15.4 (4.6—28.7) 12.9 (0.3—42.3)
Peak 17.2 (2.9—38.4) 12.1 (5.6—43.1) 16.8 (5.4—32.6) 12.9 (0.4—42.3)
Nadir 8.3 (2.2—33.2) 9.7 (4.8—41.4) 10.6 (3.1—24.1) 9.1 (0.3—35.7)
MAP, mmHg
Day 0 90 (73—123) 90 (72—113) 93 (57—137) 93 (57—157)
Nadir 80 (50—120) 83 (62—110) 80 (57—110) 83 (57—120)
GCS
Day 0 15 (10—15) 15 (8—15) 15 (8—15) 15 (5—15)
Nadir 15 (10—15) 15 (3—15) 15 (8—15) 15 (3—15)
Septic shock (n = 8) No septic shock (n = 46) Septic shock (n = 6) No septic shock (n = 152)
Temperature, 8C
Day 0 39.1 (38.6—40.0) 38.7 (38.2—40.0) 38.6 (38.4—39.9) 39.0 (38.0—41.3)
Peak 39.5 (39.0—40.4) 39.1 (38.3—40.3) 39.1 (38.6—39.9) 39.2 (38.3—41.3)
Respiratory rate, b/min
Day 0 36 (20—48) 24 (10—50) 30 (20—36) 24 (13—48) 0.028 SS
Peak 36 (17—48) 24 (12—54) 30 (24—48) 30 (14—56) 0.017 SS
Heart rate, b/min
Day 0 118 (96—154) 104 (60—148) 100 (80—116) 100 (56—160) 0.027 HI
Peak 126 (96—170) 110 (80—156) 106 (84—124) 104 (76—160) 0.008 HI
Leukocytes, 109/l
Day 0 20.6 (7.0—38.4) 12.0 (2.6—41.4) 14.0 (8.5—19.6) 12.9 (0.3—42.3)
Peak 26.2 (11.5—41.9) 12.0 (2.9—43.1) 16.9 (9.9—24.8) 12.9 (0.4—42.3) 0.011 SS
Nadir 20.6 (7.0—33.2) 8.9 (2.2—41.4) 13.4 (3.1—16.3) 9.2 (0.3—35.7) 0.029 SS
MAP, mmHg
Day 0 84 (72—110) 90 (73—123) 98 (90—123) 93 (57—157) 0.047 HI
Nadir 77 (50—100) 83 (62—120) 83 (70—103) 83 (57—120)
GCS
Day 0 15 (15—15) 15 (8—15) 13 (8—15) 15 (5—15) 0.004 HI
0.036 SS
0.001 I
Nadir 15 (3—15) 15 (3—15) 13 (8—15) 15 (3—15) 0.006 SS
Median (range). MAP,mean arterial pressure; GCS, Glasgow Coma Scale score; HI, hospital-acquired infection; BI, bloodstream infection; SS,
septic shock; I, interaction.
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response variables did not independently contribute to
bloodstream infection in predicting septic shock, and to a
low nadir GSC score and septic shock in predicting mortality.
Overall, premorbid conditions and foci of infection did not
contribute to these predictions.Discussion
We studied the role of the innate immune response in trying
to explain higher rates of bloodstream infection, septic
shock, and mortality in febrile patients on medical wards
after hospital- than community-acquired infections. Even











Day 0 7 (3—43) 8 (4—28) 13 (5—52) 8 (2—35) 0.028 HI
0.005 BI
Peak 10 (5—43) 10 (4—53) 18 (8—59) 10 (4—101) 0.018 HI
0.010 BI, I
sPLA2, ng/ml
Day 0 140 (12—394) 104 (5—1500) 413 (18—1500) 127 (1—1500) 0.027 HI
0.031 I
Peak 206 (18—1580) 181 (15—1500) 477 (50—1500) 213 (3—1760) 0.023 BI
IL-6, pg/ml
Day 0 67 (4—1580) 29 (3—3502) 56 (10—10 000) 26 (1—454) 0.004 BI
Peak 67 (4—1500) 26 (4—3502) 75 (12—10 000) 31 (2—673) <0.001 BI
Procalcitonin, ng/ml
Day 0 0.5 (0.08—69) 0.5 (0.08—33) 4 (0.08—279) 0.5 (0.08—57) 0.048 HI
0.014 BI
0.017 I
Peak 3 (0.09—502) 1 (0.08—80) 5 (0.08—279) 0.9 (0.08—615) 0.002 BI
Elastase-a1-antitrypsin, ng/ml
Day 0 100 (26—403) 86 (28—1369) 155 (36—1198) 89 (10—801) 0.037 HI
0.001 BI










Day 0 16 (7—43) 7 (3—28) 10 (6—17) 9 (2—52) 0.008 SS
0.050 I
Peak 16 (12—43) 9 (4—53) 13 (6—36) 11 (4—101) 0.008 SS
0.050 I
sPLA2, ng/ml
Day 0 371 (79—1500) 97 (5—1500) 320 (18—1500) 175 (1—1500)
Peak 750 (259—1500) 155 (15—1500) 320 (50—1500) 254 (2—1760) 0.016 SS
IL-6, pg/ml
Day 0 564 (15—3502) 26 (2—1026) 29 (13—175) 30 (1—10 000) 0.010 HI
0.002 SS
0.003 I
Peak 564 (59—3502) 24 (4—1026) 58 (14—175) 36 (2—10 000) 0.014 HI
0.001 SS, I
Procalcitonin, ng/ml
Day 0 19 (0.3—31) 0.4 (0.08—69) 0.5 (0.08—4) 0.8 (0.08—179) 0.004 I




Day 0 164 (51—1369) 84 (26—256) 131 (82—1198) 92 (10—1065) 0.001 SS
Peak 330 (73—1369) 105 (38—662) 189 (128—1198) 114 (11—1261) <0.001 SS
Non-survivors (n = 13) Survivors (n = 41) Non-survivors (n = 10) Survivors (n = 148)
C3a, nmol/l
Day 0 11 (4—43) 7 (3—28) 13 (3—25) 9 (2—52) 0.007 NS
Peak 14 (4—43) 9 (4—53) 16 (7—36) 10 (4—101) 0.008 NS
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Table 3 (Continued )
Non-survivors (n = 13) Survivors (n = 41) Non-survivors (n = 10) Survivors (n = 148)
sPLA2, ng/ml
Day 0 281 (15—1500) 87 (5—1500) 290 (34—1500) 173 (1—1500) 0.015 NS
Peak 394 (15—1500) 156 (15—1500) 903 (156—1760) 244 (3—1500) 0.010 NS
IL-6, pg/ml
Day 0 192 (15—3502) 24 (3—1580) 102 (13—10 000) 26 (1—8952) <0.001NS
Peak 259 (16—3502) 20 (4—1580) 116 (14—10 000) 32 (2—8952) <0.001 NS
Procalcitonin, ng/ml
Day 0 1 (0.08—26) 0.3 (0.08—69) 0.5 (0.08—123) 0.8 (0.08—279)
Peak 5 (0.1—47) 0.9 (0.08—502) 2 (0.14—123) 1 (0.08—615)
Elastase-a1-antitrypsin, ng/ml
Day 0 141 (26—1369) 84 (29—256) 143 (47—1198) 92 (10—1065) 0.001 NS
Peak 206 (38—1369) 110 (40—662) 197 (118—1198) 109 (11—1261) <0.001 NS
Median (range). C3a, complement C3 activation product; sPLA2, secretory phospholipase A2; IL-6, interleukin 6; HI, hospital-acquired
infection; BI, bloodstream infection; SS, septic shock; NS, non-survival; I, interaction. Time to inclusion as a covariate did not contribute.
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vated innate immunity in hospital-acquired infections, the
rates of septic shock and mortality were not increased by
suppression of innate immune responses, independent of
clinical focus of infection. In contrast, our results suggest
that an augmented host response to infection can partly
account for higher rates of septic shock and mortality from
hospital-acquired infections, independent from bloodstream
infection. Hence, proinflammatory factors may be particu-
larly useful to predict a downhill course in hospital-acquired
infections.
Most of the studies on hospital-acquired vs. community-
acquired infections suggest that the mortality rate of
patients with the former is higher, even if not associated
with an overt immunocompromised state,8,11 but mechan-
isms are still poorly understood. We excluded patients on
active cytostatic treatment and with other known overt
immune deficiencies. The higher rates of septic shock and
associated mortality of hospital- vs. community-acquired
infections can be largely attributed to more frequent (and
perhaps necessary) use of devices/interventions in the hos-
pital, as noted already in our previous study, suggesting that
external rather than patient-related factors contribute to
higher mortality from hospital-acquired infections.9 Our data
thus support the relatively high incidence of hospital-
acquired bloodstream infections and associated poor out-
come reported by others, even though usually not compared
to community-acquired infections.2,6,7 The clinical predic-
tors of bloodstream infection and septic shock otherwise
agree with other studies.10,11,24 However, since septic shock
was defined according to the SIRS criteria we cannot exclude
the fact that some of these predictive values were caused by
virtue of definition.
Our study also suggests that the innate immune response
may be more helpful in predicting a downhill course than
clinical variables, particularly during hospital-acquired
infections. Indeed, it supports the case that an augmented
rather than a suppressed innate immune response8 together
with bloodstream infection contributes to septic shock devel-
opment and thus ultimate mortality in hospital-acquiredinfections. An augmented response may have contributed
to mortality, particularly in hospital-acquired infections,
even though plasma levels were similarly elevated in non-
survivors from hospital- and community-acquired infections.
We evaluated all cause mortality so that some deaths may
have occurred unrelated to infection, and, indeed, circulat-
ing IL-6 was higher in patients considered to have died
directly as a consequence of hospital- than of community-
acquired infection.
We can only speculate on the causes of an augmented
innate immune response as compared to community-
acquired infections, including more virulent microbial strains
in non-bloodstream infections, greater immune cell respon-
siveness, or less adequate antibiotic therapy during hospital-
acquired infections, even though adequate antibiotic ther-
apy may enhance rather than suppress the innate immune
response by potential release of toxic microbial products.33—
35 In any case, a time lead bias and focus differences may not
have played a major role. We did not try to evaluate the
complex issue of appropriateness of antibiotic therapy. How-
ever, since all patients were treated in the same medical
wards, we may assume equally appropriate treatment in the
study groups.
We did not measure anti-inflammatory factors, so that we
cannot exclude that a greater release of pro-inflammatory
factors during hospital-acquired infections progressing to
septic shock and death was counterbalanced by greater
release of anti-inflammatory factors.3,4,17,18,23,26,29,31,32
Bloodstream infection was associated with a somewhat
lesser immune response in hospital- than in community-
acquired infections, and this may relate in part to the
greater predisposing contribution of devices and interven-
tions. We can only speculate on other contributory factors,
including less virulent strains in hospital-acquired blood-
stream infections.33 The phenomenon may render innate
immunity variables less helpful in the early diagnosis of
bloodstream infection in hospital- than in community-
acquired infection.
The prediction of septic shock and associated mortality on
the basis of the innate immune response variables has been
Figure 1 Bloodstream infection in hospital-acquired vs. community-acquired infections, on days 0, 1, and 2, for: (A) interleukin-6
(IL-6, p = 0.026 or lower for bloodstream infection); (B) procalcitonin (PCT, p = 0.014 or lower for bloodstream infection and p = 0.048
or lower for hospital-acquired infection days 0 and 2, and p = 0.017 for interaction on day 0); (C) elastase-a1-antitrypsin ( p = 0.006 or
lower for bloodstream infection and p = 0.037 for hospital-acquired infection on day 0). Symbols: squares = bloodstream infection
(n = 46); circles = no bloodstream infection (n = 166); continuous lines = hospital-acquired infection (n = 54); dashed lines = commu-
nity-acquired infection (n = 158). Mean  SEM.
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studies, variables, conditions, microbes, individuals, and
genetics.1,3,4,13—32 Our data suggest that part of the varia-
bility of predictors reported may have been caused in part by
differences in case-mix of hospital- vs. community-acquired
infections. Indeed, the innate immune response, particularly
that of IL-6, may depend on the speed of septic shock
development and clinical deterioration, and seems more
predictive, as can be deducted from the literature, wheninfection and sepsis are hospital- rather than community-
acquired.14,18,19,25,32 Nevertheless, across studies, circulat-
ing IL-6 appears the most consistent factor that indepen-
dently contributes to prediction of sepsis and its severity,
even when declining after start of therapy.1,4,12—25,27,29,31
Optimal PCT cutoff levels for prediction of infection and its
course may also depend on the environmental origin of
infection and its severity.25,30 Our results nevertheless agree
with studies showing the value of PCT for predicting a
Figure 2 Septic shock in hospital-acquired vs. community-acquired infections, on days 0, 1, and 2, for: (A) interleukin-6 (IL-6,
p = 0.003 or lower for septic shock, p = 0.010 for hospital-acquired infection day 0, p = 0.015 or lower for interaction day 0 and 1); (B)
procalcitonin (PCT, p = 0.010 for septic shock day 1, p = 0.006 for hospital-acquired infection day 1, and p = 0.007 or lower for
interaction days 0 and 2); (C) elastase-a1-antitrypsin ( p = 0.009 or lower for septic shock, p = 0.018 for hospital-acquired infection day
2, and p = 0.006 for interaction day 2). Symbols: squares = septic shock (n = 14); circles = no septic shock (n = 198); continuous
lines = hospital-acquired infection (n = 54); dashed lines = community-acquired infection (n = 158). Mean  SEM.
668 A.B.J. Groeneveld, C.E. Hackdownhill course of sepsis and septic shock in the hospi-
tal.1,19,21,22,27,29,30 We did not include surgical or critically
ill patients, more commonly studied in hospital-acquired
infections than medical patients,1—6 so that our conclusions
may not apply to the former. However, post-surgical sepsis
may be well predicted by IL-6 and PCT,4,5 as in our medical
patients, but in contrast to a recent meta-analysis on the
latter.30 Conversely, our data suggest that neutrophil degra-
nulation is an important contributor to a downhill course ofinfection, as already suggested, even in post-surgical or
trauma patients.28
In conclusion, our data suggest that innate immunity is
not impaired during hospital-acquired infections in febrile,
presumably immunocompetent patients on medical
wards. In contrast, IL-6 may be more useful to predict a
downhill course of hospital- than of community-acquired
infections.
Conflict of interest: No conflict of interest to declare.
Figure 3 Non-survivors in hospital-acquired vs. community-acquired infections, on days 0, 1, and 2, for: (A) interleukin-6 (IL-6,
p = 0.004 or lower for non-survivors); (B) procalcitonin (PCT); (C) elastase-a1-antitrypsin ( p = 0.014 or lower for non-survivors).
Symbols: squares = non-survivors (n = 23); circles = survivors (n = 189); continuous lines = hospital-acquired infection (n = 54); dashed
lines = community-acquired infection (n = 158). Mean  SEM.
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